Cargando…
The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543421/ https://www.ncbi.nlm.nih.gov/pubmed/34697413 http://dx.doi.org/10.1038/s41423-021-00779-5 |
| _version_ | 1784589631972442112 |
|---|---|
| author | Arora, Prerna Rocha, Cheila Kempf, Amy Nehlmeier, Inga Graichen, Luise Winkler, Martin S. Lier, Martin Schulz, Sebastian Jäck, Hans-Martin Cossmann, Anne Stankov, Metodi V. Behrens, Georg M. N. Pöhlmann, Stefan Hoffmann, Markus |
| author_facet | Arora, Prerna Rocha, Cheila Kempf, Amy Nehlmeier, Inga Graichen, Luise Winkler, Martin S. Lier, Martin Schulz, Sebastian Jäck, Hans-Martin Cossmann, Anne Stankov, Metodi V. Behrens, Georg M. N. Pöhlmann, Stefan Hoffmann, Markus |
| author_sort | Arora, Prerna |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8543421 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-85434212021-10-25 The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency Arora, Prerna Rocha, Cheila Kempf, Amy Nehlmeier, Inga Graichen, Luise Winkler, Martin S. Lier, Martin Schulz, Sebastian Jäck, Hans-Martin Cossmann, Anne Stankov, Metodi V. Behrens, Georg M. N. Pöhlmann, Stefan Hoffmann, Markus Cell Mol Immunol Correspondence Nature Publishing Group UK 2021-10-25 2021-12 /pmc/articles/PMC8543421/ /pubmed/34697413 http://dx.doi.org/10.1038/s41423-021-00779-5 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Arora, Prerna Rocha, Cheila Kempf, Amy Nehlmeier, Inga Graichen, Luise Winkler, Martin S. Lier, Martin Schulz, Sebastian Jäck, Hans-Martin Cossmann, Anne Stankov, Metodi V. Behrens, Georg M. N. Pöhlmann, Stefan Hoffmann, Markus The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title_full | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title_fullStr | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title_full_unstemmed | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title_short | The spike protein of SARS-CoV-2 variant A.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| title_sort | spike protein of sars-cov-2 variant a.30 is heavily mutated and evades vaccine-induced antibodies with high efficiency |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8543421/ https://www.ncbi.nlm.nih.gov/pubmed/34697413 http://dx.doi.org/10.1038/s41423-021-00779-5 |
| work_keys_str_mv | AT aroraprerna thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT rochacheila thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT kempfamy thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT nehlmeieringa thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT graichenluise thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT winklermartins thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT liermartin thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT schulzsebastian thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT jackhansmartin thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT cossmannanne thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT stankovmetodiv thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT behrensgeorgmn thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT pohlmannstefan thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT hoffmannmarkus thespikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT aroraprerna spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT rochacheila spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT kempfamy spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT nehlmeieringa spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT graichenluise spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT winklermartins spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT liermartin spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT schulzsebastian spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT jackhansmartin spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT cossmannanne spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT stankovmetodiv spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT behrensgeorgmn spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT pohlmannstefan spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency AT hoffmannmarkus spikeproteinofsarscov2varianta30isheavilymutatedandevadesvaccineinducedantibodieswithhighefficiency |